Physician profile
Jing Xi
NPI 1275983926
$62,722.61
in general payments reported to CMS, 2019-2025
36 companies · $24K in 2025
The $24K reported for 2025 was more than what 94% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $357 · 2020: $250 · 2021: $150 · 2022: $224 · 2023: $5,335 · 2024: $32K · 2025: $24K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $32K · Consulting Fee: $22K · Food and Beverage: $4,942 · Travel and Lodging: $2,852 · Honoraria: $200 · Education: $143.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $31,570.00 |
| Consulting Fee | $22,035.00 |
| Food and Beverage | $4,941.76 |
| Travel and Lodging | $2,852.36 |
| Honoraria | $200.00 |
| Education | $142.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $32,171.27 | 2023-2025 | Trodelvy |
| Astrazeneca Pharmaceuticals LP | $19,002.13 | 2023-2025 | Truqap, Lynparza, Enhertu |
| Stemline Therapeutics INC. | $5,021.54 | 2024-2025 | Orserdu |
| Lilly USA, LLC | $2,212.48 | 2024 | Verzenio |
| Daiichi Sankyo INC. | $431.24 | 2023-2025 | Enhertu, Vanflyta |
| Genmab U.S., INC. | $395.89 | 2023-2025 | Tivdak, Epkinly |
| Tersera Therapeutics LLC | $375.94 | 2025 | Zoladex |
| Glaxosmithkline, LLC. | $297.02 | 2023-2025 | Jemperli, Ojjaara, Zejula |
| Leica Microsystems INC. | $280.00 | 2025 | |
| Merck Sharp & Dohme LLC | $270.99 | 2022-2025 | Keytruda, Lynparza |
| Novartis Pharmaceuticals Corporation | $215.13 | 2023-2025 | |
| Exelixis INC. | $196.22 | 2023-2025 | Cabometyx |
| Amgen INC. | $187.91 | 2020-2025 | |
| Myriad Genetic Laboratories, INC. | $187.06 | 2022-2024 | Mychoice Cdx, Bracanalysis Cdx, Myrisk |
| Beigene USA, INC. | $175.00 | 2021-2023 | Brukinsa |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $149.99 | 2020-2021 | |
| Tempus Ai, INC | $144.92 | 2024 | |
| Immunogen, INC. | $134.71 | 2023 | Elahere |
| Alexion Pharmaceuticals, INC. | $121.63 | 2019 | |
| Abbvie INC. | $110.87 | 2019-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $99.99 | 2022 | |
| Astellas Pharma US INC | $99.95 | 2020 | |
| Genentech USA, INC. | $75.99 | 2019 | |
| Janssen Biotech, INC. | $66.81 | 2024 | Tecvayli, Darzalex, Talvey |
| Eisai INC. | $50.33 | 2024-2025 | |
| Otsuka America Pharmaceutical, INC. | $38.96 | 2019 | |
| Celgene Corporation | $34.26 | 2024 | Reblozyl |
| Cti Biopharma Corp. | $28.35 | 2023 | Vonjo |
| Rigel Pharmaceuticals, INC. | $26.84 | 2024 | Rezlidhia, Tavalisse |
| Pfizer INC. | $25.44 | 2019 | |
| Pharmacosmos Therapeutics INC. | $20.98 | 2023 | Monoferric |
| Taiho Oncology, INC. | $20.73 | 2024 | |
| Menarini Silicon Biosystems, INC. | $18.98 | 2024 | |
| Caris Mpi, INC. | $18.48 | 2025 | Mi Cancer Seek |
| Tactile Systems Technology INC | $14.58 | 2024 | Entre Plus, Flexitouch Plus |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jing Xi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.